Robinhood reports August 2025 customer and trading metrics
On Friday, Goldman Sachs reiterated a Neutral rating with a $57.00 price target on CRISPR Therapeutics (NASDAQ:CRSP), which currently trades at $34.26. According to InvestingPro data, analyst targets for the stock range from $32 to $268, with the consensus recommendation leaning slightly bullish at 2.04. The firm's analysis followed a meeting with key executives from CRISPR, including CFO Raju Prasad, CMO Naimish Patel, and IR Susie Kim. The discussion revolved around the company's strategic direction, its collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX) on the gene-edited therapy Casgevy, and its pipeline developments in various medical fields.
CRISPR Therapeutics, according to Goldman Sachs, appears to be shielded from the current macroeconomic uncertainties and FDA regulatory challenges. This is due to several factors, including the nature of Casgevy, which is not affected by tariffs, a robust cash position of $1.9 billion providing a financial runway into the 2030s, and a pipeline that requires limited near-term regulatory interaction. InvestingPro analysis confirms the company's strong financial position, with a current ratio of 22.07 and more cash than debt on its balance sheet, though it's worth noting the company is not yet profitable, with an EBITDA of -$447.31 million in the last twelve months.
Looking ahead, Goldman Sachs is monitoring the launch progress of Casgevy, anticipating an increase in patient cell collections in 2025 and projecting the franchise to become profitable by 2026. CRISPR Therapeutics is also expected to present initial Phase 1 study data from its in vivo gene editing cardiovascular assets, CTX310 and CTX320, in the first half of 2025. These studies aim to demonstrate a safe profile and a reduction in circulating Lp(a)/ANGPTL3 levels, which are considered benchmarks for disease control.
Additionally, CRISPR Therapeutics plans to release longer-term follow-up data from the Phase 1 study of its next-generation allogeneic CD19 CAR T therapy, CTX112, for relapsed/refractory B cell malignancies, as well as initial data from the Phase 1 study in autoimmune disease by mid-2025. The focus will be on the durability of the treatment and biomarker data to support the concept through the depth of B cell depletion.
In other recent news, CRISPR Therapeutics has received an orphan drug designation from the U.S. Food and Drug Administration for its treatment targeting follicular lymphoma. This designation is meant to encourage the development of therapies for rare diseases. In another development, CRISPR Therapeutics' Chief Operating Officer, Julianne Bruno, will step down from her position in April 2025, ending a six-year tenure with the company. The company has also seen an upgrade from Evercore ISI, with analyst Liisa Bayko raising the price target from $60 to $99, citing potential upcoming catalysts for the company's growth. Meanwhile, Citi has adjusted its price target for CRISPR Therapeutics to $82, maintaining a Buy rating, and highlighting the company's pipeline progress and upcoming data releases in 2025. The firm's Casgevy treatment is expanding globally, with over 50 treatment centers activated. These recent developments underscore the dynamic environment surrounding CRISPR Therapeutics, with significant implications for its future trajectory in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.